Objective:To observe the effects of manganese(Ⅲ)meso-tetrakis(N,N -diethylimidazolium-2-yl)porphyrin(MnTDM)in treatment of early Parkinson s disease(PD)mouse model induced by subcutaneous injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)and to discuss its possible mechanism.

A supported Mn-porphyrin catalyst has been prepared by adsorption of the cationic manganese porphyrin MnTMPyP on macroporous silica.

Synthesis of manganese porphyrin-TFO-acridine;

Purification of manganese porphyrin-TFO with thin layer chromatography;

(3R,4R)-4-acetoxy-3-[(1\'R-tert-butyl-dimethylsilyloxy)-ethyl]-2-azetidinone (4AA) was prepared from (3S,4S)-4-carboxyl-3-[(1\'R-tert-butyl-dimethylsilyloxy)-ethyl]-1-p-methoxyphenyl-2-azetidinone through two-step process,involving the decarboxylation oxidation reaction which was catalyzed by manganese porphyrin and oxidized,and the reaction of oxidation using O3.

This paper mainly introduces the inhibition function of manganese and manganese porphyrins to superoxide and hydroxyl radicals, lipid peroxidation.

Recent researches on mechanism of hydrocarbon selective oxidations with hydrogen peroxide catalyzed by metalloporphyrins including iron porphyrins and manganese porphyrins are reviewed in this paper.